{"doc_id": "si-2022-0416-reg-1", "parent_doc_id": "si-2022-0416", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "1. (1) These Regulations may be cited as the Medicinal Products (Control", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products (Control \n\nof Placing on the Market) (Amendment) Regulations 2022. \n\n(2) The Principal Regulations, the Medicinal Products (Control of Placing \non the Market) Regulations 2007 (Amendment) Regulations 2009 ( S.I. No. 3 \nof 2009 ), the Medicinal Products (Control of Placing on the Market) \nRegulations 2007 (Amendment) (No. 2) Regulations 2009 ( S.I. No. 553 of \n2009 ), the Medicinal Products (Control of Placing on the Market) Regulations \n2007 (Amendment) Regulations 2010 (No. 287 of 2010), the Medicinal \nProducts (Control of Placing on the Market) (Amendment) Regulations 2011 ( \nS.I. No. 722 of 2011 ), the Medicinal Products (Control of Placing on the \nMarket) (Amendment) Regulations 2012 ( S.I. No. 272 of 2012 ), the \nMedicinal Products (Control of Placing on the Market) (Amendment) \nRegulations 2013 ( S.I. No. 162 of 2013 ), the Medicinal Products (Control of \nPlacing on the Market) (Amendment) Regulations 2014 ( S.I. No. 151 of 2014 \n), the Medicinal Products (Control of Placing on the Market) (Amendment) \nRegulations 2018 (S.I. No. 529 of 2018), Regulation 6 of Medicinal Products \n(Safety Features On Packaging) Regulations 2019 (S.I. No. 36 of 2019), the \nMedicinal Products (Control of Placing on the Market) (Amendment) \nRegulations 2019 (S.I. No. 218 of 2019) and these Regulations may be cited \ntogether as “the Medicinal Products (Control of Placing on the Market) \nRegulations 2007 to 2022”.", "text_norm": "1 (1) regulation may cited medicinal product (control placing market) (amendment) regulation 2022 (2) principal regulation medicinal product (control placing market) regulation 2007 (amendment) regulation 2009 ( s.i no 3 2009 ) medicinal product (control placing market) regulation 2007 (amendment) (no 2) regulation 2009 ( s.i no 553 2009 ) medicinal product (control placing market) regulation 2007 (amendment) regulation 2010 (no 287 2010) medicinal product (control placing market) (amendment) regulation 2011 ( s.i no 722 2011 ) medicinal product (control placing market) (amendment) regulation 2012 ( s.i no 272 2012 ) medicinal product (control placing market) (amendment) regulation 2013 ( s.i no 162 2013 ) medicinal product (control placing market) (amendment) regulation 2014 ( s.i no 151 2014 ) medicinal product (control placing market) (amendment) regulation 2018 (s.i no 529 2018) regulation 6 medicinal product (safety feature packaging) regulation 2019 (s.i no 36 2019) medicinal product (control placing market) (amendment) regulation 2019 (s.i no 218 2019) regulation may cited together medicinal product (control placing market) regulation 2007 2022", "start_char": 743, "end_char": 2228, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-reg-2", "parent_doc_id": "si-2022-0416", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "2. These Regulations shall be deemed to have come into operation on 1", "text_raw": "2. These Regulations shall be deemed to have come into operation on 1 \n\nJanuary 2022.", "text_norm": "2 regulation shall deemed come operation 1 january 2022", "start_char": 2228, "end_char": 2316, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-reg-3", "parent_doc_id": "si-2022-0416", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "In these Regulations “Principal Regulations” means the Medicinal", "text_raw": "3. \n\nIn these Regulations “Principal Regulations” means the Medicinal \nProducts (Control of Placing on the Market) Regulations 2007 (S.I. No. 540 of \n2007).", "text_norm": "3 regulation principal regulation mean medicinal product (control placing market) regulation 2007 (s.i no 540 2007)", "start_char": 2316, "end_char": 2475, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-reg-4", "parent_doc_id": "si-2022-0416", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "4. Regulation 3(1) of the Principal Regulations is amended by substituting", "text_raw": "4. Regulation 3(1) of the Principal Regulations is amended by substituting \n\nfor the definition of “2001 Directive” the following: \n\n1 OJ No. L. 118, 20.4.2022, p.4. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd August, 2022. \n\n \n \n \n \n \n \n \n \n \n \n \n\f[416] 3 \n\n“‘2001 Directive’ means Directive 2001/83/EC of the European Parliament and \nof the Council on the Community code relating to medicinal products for \nhuman use5 (as amended);”.", "text_norm": "4 regulation 3(1) principal regulation amended substituting definition 2001 directive following 1 oj no l 118 20.4.2022 p.4 notice making statutory instrument published iris oifigiuil 23rd august 2022 416 3 2001 directive mean directive 2001 83 ec european parliament council community code relating medicinal product human use5 (as amended)", "start_char": 2475, "end_char": 2964, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-reg-5", "parent_doc_id": "si-2022-0416", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "5. Regulation 9 of the Principal Regulations is amended by substituting", "text_raw": "5. Regulation 9 of the Principal Regulations is amended by substituting \n\nfor subparagraph 6 the following: \n\n“(6) (a) The applicant for the grant of a marketing authorisation shall – \n\nbe established in an EEA State, or \n\nuntil 31 December 2024, be established in parts of the United Kingdom other \nthan Northern Ireland, where the marketing authorisation is sought pursuant to \nthe mutual recognition or the decentralised procedure laid down in Chapter 4 of \nthe 2001 Directive, \n\nand shall be responsible for the accuracy of any documents and \ndata submitted in support of any such application, \n\n(b) The applicant for the renewal of a marketing authorisation shall – \n\nbe established in an EEA State, or \n\n(i) \n(ii) until 31 December 2024, be established in parts of the \n\nUnited Kingdom other than Northern Ireland, \n\nand shall be responsible for the accuracy of any documents and \ndata submitted in support of any such application, \n\n(c) until 31 December 2024, \n\nthe Board may extend marketing \n already granted prior to 20 April 2022 to marketing \nauthorisations \nauthorisation holders established in parts of the United Kingdom other than \nNorthern Ireland, \n\n(d) marketing authorisations granted or extended by the Board in \naccordance with subparagraphs (a)(ii), b(ii) or (c) shall cease to be valid at the \nlatest on 31 December 2026, unless the marketing authorisation has been \ntransferred to a holder established in an EEA State prior to that date, \n\n(e) The applicant for the grant or renewal of a certificate of registration and \na certificate of traditional-use registration shall be established in an EEA State \nand shall be responsible for the accuracy of any documents and data submitted \nin support of any such application.”", "text_norm": "5 regulation 9 principal regulation amended substituting subparagraph 6 following (6) (a) applicant grant marketing authorisation shall - established eea state 31 december 2024 established part united kingdom northern ireland marketing authorisation sought pursuant mutual recognition decentralised procedure laid chapter 4 2001 directive shall responsible accuracy document data submitted support application (b) applicant renewal marketing authorisation shall - established eea state (i) (ii) 31 december 2024 established part united kingdom northern ireland shall responsible accuracy document data submitted support application (c) 31 december 2024 board may extend marketing already granted prior 20 april 2022 marketing authorisation authorisation holder established part united kingdom northern ireland (d) marketing authorisation granted extended board accordance subparagraphs (a)(ii) b(ii) (c) shall cease valid latest 31 december 2026 unless marketing authorisation transferred holder established eea state prior date (e) applicant grant renewal certificate registration certificate traditional-use registration shall established eea state shall responsible accuracy document data submitted support application", "start_char": 2964, "end_char": 4713, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-reg-6", "parent_doc_id": "si-2022-0416", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "6. Regulation 15 of the Principal Regulations is amended by substituting", "text_raw": "6. Regulation 15 of the Principal Regulations is amended by substituting \n\nfor subparagraph 5 the following: \n“(5) (a) The holder of a marketing authorisation granted or renewed shall – \n\nbe established in an EEA State, or \n\n(i) \n(ii) until 31 December 2024, be established in parts of the \n\nUnited Kingdom other than Northern Ireland, \n\nand shall be responsible for the accuracy of any documents and \ndata submitted in connection with such authorisation, \n\n5 OJ No. L. 311, 28.11.2001, p.67. \n\n \n \n \n \n\f4 [416] \n\n(b) until 31 December 2024, the Board may extend marketing \nauthorisations already granted prior to 20 April 2022 to \nmarketing authorisation holders established in parts of the \nUnited Kingdom other than Northern Ireland, \n\n(c) marketing authorisations granted or extended by the Board in \naccordance with subparagraphs (a)(ii) or (b) shall cease to be \nvalid at the latest on 31 December 2026, unless the marketing \nauthorisation has been transferred to a holder established in an \nEEA State prior to that date, \n\n(d) The holder of a certificate of registration or certificate of \ntraditional-use registration, granted or renewed shall be \nestablished in an EEA State and shall be responsible for the \naccuracy of any documents and data submitted in connection \nwith such authorisation or certificate.”", "text_norm": "6 regulation 15 principal regulation amended substituting subparagraph 5 following (5) (a) holder marketing authorisation granted renewed shall - established eea state (i) (ii) 31 december 2024 established part united kingdom northern ireland shall responsible accuracy document data submitted connection authorisation 5 oj no l 311 28.11.2001 p.67 4 416 (b) 31 december 2024 board may extend marketing authorisation already granted prior 20 april 2022 marketing authorisation holder established part united kingdom northern ireland (c) marketing authorisation granted extended board accordance subparagraphs (a)(ii) (b) shall cease valid latest 31 december 2026 unless marketing authorisation transferred holder established eea state prior date (d) holder certificate registration certificate traditional-use registration granted renewed shall established eea state shall responsible accuracy document data submitted connection authorisation certificate", "start_char": 4713, "end_char": 6034, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-reg-7", "parent_doc_id": "si-2022-0416", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "7. The Principal Regulations are amended by inserting after Part 9 the", "text_raw": "7. The Principal Regulations are amended by inserting after Part 9 the \n\nfollowing Part: \n\n“PART 10 \n\nDEROGATIONS", "text_norm": "7 principal regulation amended inserting part 9 following part part 10 derogation", "start_char": 6034, "end_char": 6150, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-reg-41", "parent_doc_id": "si-2022-0416", "section_id": "reg-41", "section_label": "Regulation 41.", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "41. (1) By 20 May 2022, the Board shall establish, notify to the", "text_raw": "41. (1) By 20 May 2022, the Board shall establish, notify to the \nCommission and publish on its website a list of medicinal products to which it \nhas applied or intends to apply the derogations as set out in Regulations 9(6) \nand 15(5) of these Regulations. \n\n(2) The Board shall ensure that the list referred to in paragraph (1) is \n\nupdated at least on a six-monthly basis. \n\n(3) Any marketing authorisation holder who intends to avail of the \nderogations set out in Regulations 9(6) and 15(5) of these Regulations shall \nnotify the Board and ensure that the relevant medicinal product is included on \nthe list referred to in paragraph (1) before the relevant medicinal product is \nplaced on the market in the State.” \n\nGIVEN under the Official Seal of the Minister for Health, \n\n18 August, 2022. \n\nMUIRIS O'CONNOR, \n\nA person authorised under section 15 of the Ministers and \nSecretaries Act 1924 to authenticate the seal of the \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[416] 5", "text_norm": "41 (1) 20 may 2022 board shall establish notify commission publish website list medicinal product applied intends apply derogation set regulation 9(6) 15(5) regulation (2) board shall ensure list referred paragraph (1) updated least six-monthly basis (3) marketing authorisation holder intends avail derogation set regulation 9(6) 15(5) regulation shall notify board ensure relevant medicinal product included list referred paragraph (1) relevant medicinal product placed market state given official seal minister health 18 august 2022 muiris connor person authorised section 15 minister secretary act 1924 authenticate seal minister health 416 5", "start_char": 6150, "end_char": 7143, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
{"doc_id": "si-2022-0416-explanatory-note", "parent_doc_id": "si-2022-0416", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 416 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninterpretation) \n\nThe main purpose of these Regulations is to implement Articles 2(2) and 2(11) \nof Directive (EU) 2022/642 of the European Parliament and of the Council of \n12 April 2022, which amend Directive 2001/83/EC as regards derogations \nfrom certain obligations concerning certain medicinal products for human use. \n\n \n \n \n \n \n \n\f6 [416] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-438) 75. 8/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) main purpose regulation implement article 2(2) 2(11) directive (eu) 2022 642 european parliament council 12 april 2022 amend directive 2001 83 ec regard derogation certain obligation concerning certain medicinal product human use 6 416 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-438) 75 8 22 propylon", "start_char": 7143, "end_char": 8071, "source_path": "downloads\\2022\\2022_0415.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16a654bdddd4f124dddaa5c59a12820d6979b7109fe67c56127e483b41e07f27", "cross_refs": []}
